Bronchial asthma
Conditions
Interventions
Add tulobuterol transdermal therapeutic system(TTS) 2 mg once daily to the current medication
Add inhaled salmeterol 50 mcg twice daily to the current medication
Sponsors
Kyoto University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Mild or moderate asthma 2. Poorly controlled patients who need additional controler medication to the current treatment including inhaled corticosteroid 3. Astmatic patients diagnosed definitely by airway responsiveness test or airway reversibility test 4. Never smokers or ex-smokers of < 10 pack-years who quit smoking for > one year
Exclusion criteria
Exclusion criteria: 1. Patients with concomitant respiratory disease that may interfere with evaluation of outcomes 2. Patients with hypersensitivity to salmeterol or tulobuterol 3. Patients with dermal disease potentially intolerant to transdermal medication 4. Patients with hyperthyroidism or cardiovascular disease which preclude a use of beta-agonist 5. Pregnancy or lactation 6. Patients who are considered inappropriate by physicians in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parameters of impulse oscillometry | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Indices of pulmonary function 2. Exhaled nitric oxide concentrations 3. degree of dyspnea (using Medical Research Council dyspnea scale) 4. Quality of life (using St. George's Respiratory Questionnaire) 5. ACT(asthma control test) 6. clinical symptoms(such as wheezing) | — |
Countries
Japan
Contacts
Public ContactHideki Inoue
Kyoto University Graduate School of Medicine Department of Respiratory Medicine
Outcome results
None listed